Literature DB >> 16281052

Metalloendoprotease cleavage triggers gelsolin amyloidogenesis.

Lesley J Page1, Ji Young Suk, Mary E Huff, Hee-Jong Lim, John Venable, John Yates, Jeffery W Kelly, William E Balch.   

Abstract

Amyloid diseases like Alzheimer's disease and familial amyloidosis of Finnish type (FAF) stem from endoproteolytic cleavage of a precursor protein to generate amyloidogenic peptides that accumulate as amyloid deposits in a tissue-specific manner. FAF patients deposit both 8 and 5 kDa peptides derived from mutant (D187Y/N) plasma gelsolin in the extracellular matrix (ECM). The first of two aberrant sequential proteolytic events is executed by furin to yield a 68 kDa (C68) secreted fragment. We now identify the metalloprotease MT1-matrix metalloprotease (MMP), an integral membrane protein active in the ECM, as a protease that processes C68 to the amyloidogenic peptides. We further demonstrate that ECM components are capable of accelerating gelsolin amyloidogenesis. Proteolysis by MT1-MMP-like proteases proximal to the unique chemical environment of the ECM offers an explanation for the tissue-specific deposition observed in FAF and provides critical insight into new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16281052      PMCID: PMC1356312          DOI: 10.1038/sj.emboj.7600872

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  57 in total

1.  The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.

Authors:  A Amour; C G Knight; A Webster; P M Slocombe; P E Stephens; V Knäuper; A J Docherty; G Murphy
Journal:  FEBS Lett       Date:  2000-05-19       Impact factor: 4.124

Review 2.  Gelsolin, a multifunctional actin regulatory protein.

Authors:  H Q Sun; M Yamamoto; M Mejillano; H L Yin
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

3.  The amyloidogenicity of gelsolin is controlled by proteolysis and pH.

Authors:  G Ratnaswamy; E Koepf; H Bekele; H Yin; J W Kelly
Journal:  Chem Biol       Date:  1999-05

4.  A sulfated proteoglycan aggregation factor mediates amyloid-beta peptide fibril formation and neurotoxicity.

Authors:  J McLaurin; T Franklin; W J Kuhns; P E Fraser
Journal:  Amyloid       Date:  1999-12       Impact factor: 7.141

5.  Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors.

Authors:  E Llano; A M Pendás; J P Freije; A Nakano; V Knäuper; G Murphy; C López-Otin
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

6.  Functional consequences of amyloidosis mutation for gelsolin polypeptide -- analysis of gelsolin-actin interaction and gelsolin processing in gelsolin knock-out fibroblasts.

Authors:  H Kangas; I Ulmanen; T Paunio; D J Kwiatkowski; M Lehtovirta; A Jalanko; L Peltonen
Journal:  FEBS Lett       Date:  1999-07-09       Impact factor: 4.124

Review 7.  Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis.

Authors:  S S Molloy; E D Anderson; F Jean; G Thomas
Journal:  Trends Cell Biol       Date:  1999-01       Impact factor: 20.808

8.  The biological and chemical basis for tissue-selective amyloid disease.

Authors:  Yoshiki Sekijima; R Luke Wiseman; Jeanne Matteson; Per Hammarström; Sean R Miller; Anu R Sawkar; William E Balch; Jeffery W Kelly
Journal:  Cell       Date:  2005-04-08       Impact factor: 41.582

9.  Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase.

Authors:  T Shimada; H Nakamura; E Ohuchi; Y Fujii; Y Murakami; H Sato; M Seiki; Y Okada
Journal:  Eur J Biochem       Date:  1999-06

10.  MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.

Authors:  K Holmbeck; P Bianco; J Caterina; S Yamada; M Kromer; S A Kuznetsov; M Mankani; P G Robey; A R Poole; I Pidoux; J M Ward; H Birkedal-Hansen
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

View more
  21 in total

1.  Discovery and characterization of a mammalian amyloid disaggregation activity.

Authors:  Amber N Murray; James P Solomon; Ya-Juan Wang; William E Balch; Jeffery W Kelly
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

2.  Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase.

Authors:  Markus P Kummer; Hiroko Maruyama; Claudia Huelsmann; Sandra Baches; Sascha Weggen; Edward H Koo
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

Review 3.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

4.  Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model.

Authors:  Wouter Van Overbeke; Adriaan Verhelle; Inge Everaert; Olivier Zwaenepoel; Joël Vandekerckhove; Claude Cuvelier; Wim Derave; Jan Gettemans
Journal:  Mol Ther       Date:  2014-07-15       Impact factor: 11.454

5.  A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction.

Authors:  Anske Van den Abbeele; Sarah De Clercq; Ariane De Ganck; Veerle De Corte; Berlinda Van Loo; Sameh Hamdy Soror; Vasundara Srinivasan; Jan Steyaert; Joël Vandekerckhove; Jan Gettemans
Journal:  Cell Mol Life Sci       Date:  2010-02-07       Impact factor: 9.261

Review 6.  Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.

Authors:  James P Solomon; Lesley J Page; William E Balch; Jeffery W Kelly
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-02-24       Impact factor: 8.250

7.  The 8 and 5 kDa fragments of plasma gelsolin form amyloid fibrils by a nucleated polymerization mechanism, while the 68 kDa fragment is not amyloidogenic.

Authors:  James P Solomon; Isaac T Yonemoto; Amber N Murray; Joshua L Price; Evan T Powers; William E Balch; Jeffery W Kelly
Journal:  Biochemistry       Date:  2009-12-08       Impact factor: 3.162

8.  Switch region for pathogenic structural change in conformational disease and its prediction.

Authors:  Xin Liu; Ya-Pu Zhao
Journal:  PLoS One       Date:  2010-01-11       Impact factor: 3.240

Review 9.  Animal models of human amyloidoses: are transgenic mice worth the time and trouble?

Authors:  Joel N Buxbaum
Journal:  FEBS Lett       Date:  2009-07-20       Impact factor: 4.124

10.  Competition between intramolecular and intermolecular interactions in an amyloid-forming protein.

Authors:  Katy E Routledge; Gian Gaetano Tartaglia; Geoffrey W Platt; Michele Vendruscolo; Sheena E Radford
Journal:  J Mol Biol       Date:  2009-04-23       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.